Merck MRK announced that it is discontinuing the development of two of its cancer candidates, vibostolimab and favezelimab.

Merck is discontinuing the phase 3 KeyVibe-003 and KeyVibe-007 trials, which are evaluating the fixed-dose combination of vibostolimab and pembrolizumab in certain patients with non-small cell lung ...

Merck (MRK) announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an ...

US pharma giant Merck & Co has announced the discontinuation of the clinical development programs for vibostolimab, an ...

Merck halts vibostolimab and favezelimab trials due to efficacy results, prioritizing its oncology pipeline while the FDA ...

Both vibostolimab and favezelimab have had disappointing runs leading up to their termination, sustaining several late-stage ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical ...

Out with the old, in with the new. The end of the year in biopharma is typically marked by pipeline clear outs, and 2024 is ...

The drugmaker said that the agents vibostolimab and favezelimab failed to show benefit across numerous trials.